Roszdravnadzor Has Registered Two Test Systems For The Determination Of Antibodies To SARS-CoV-2

Roszdravnadzor has registered two test systems for the determination of antibodies to SARS-CoV-2

Registration certificates were received by the National Medical Research Center of Hematology and the Federal Medical and Biological Agency of Russia

Photo: pixabay.com

One of the test systems was developed by specialists from the National Medical Research Center of Hematology in cooperation with the Institute of Molecular Biology. As the head of the laboratory of transplant immunology, Grigory Efimov, said on his Facebook page, the research center has already transferred test systems to several Moscow hospitals for testing doctors working in the "red zone".

In the next few days, the center will launch a service for testing the presence of antibodies in the blood for everyone. Now experts are thinking over a mechanism that will make testing available to a large number of people. It will be possible to register through the site of the center www.blood.ru.

“This analysis does not detect the virus itself, but the response of the immune system to it. The immune response does not appear immediately, but it lasts for a very long time. Therefore, such a test system is ideal for those who have not been tested for the virus itself during illness. If a person has antibodies in his blood, it means that he has already met with COVID-19,”said Efimov.

The registration of test systems for the determination of antibodies to coronavirus infection was also announced by the Federal Scientific and Clinical Center for Physical and Chemical Medicine of the FMBA of Russia.

“The new test system is a 96-well plate with optical recording of results. Detection of antibodies (immunoglobulins) of class G is performed by enzyme-linked immunosorbent assay (ELISA). It is the class G immunoglobulins that help destroy antigens until the infection is completely defeated and continue to circulate in the human blood in the future, providing immunity to re-infection,”the FMBA press service said.

Detection of antibodies to SARS-CoV-2 in the patient's serum will allow tracking seroconversion, that is, the period of time over which antibodies are produced in the body, and, therefore, the process of resolving the disease.